⌘K
Loading ticker…
As of 2026-08-24, PharmaCyte Biotech, Inc. Common Stock (PMCB) has a 3-month relative strength percentile of 12 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.7%, relative volume 0.47×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PMCB is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -19.1% / -29.8%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
PMCB appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $34K notional.
Held by 1 ETFs · $34K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $34K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PMCB Jan avg: 3.84% median: 1.81% win: 75% σ: 6.37% n: 4 2022-04-12 → 2026-07-31 | PMCB Feb avg: -1.53% median: -0.15% win: 50% σ: 11.07% n: 4 2022-04-12 → 2026-07-31 | PMCB Mar avg: -5.71% median: -3.29% win: 25% σ: 17.37% n: 4 2022-04-12 → 2026-07-31 | PMCB Apr avg: 0.97% median: 0.34% win: 60% σ: 7.65% n: 5 2022-04-12 → 2026-07-31 | PMCB May avg: -0.54% median: -1.29% win: 40% σ: 12.86% n: 5 2022-04-12 → 2026-07-31 | PMCB Jun avg: -2.65% median: -2.61% win: 20% σ: 6.24% n: 5 2022-04-12 → 2026-07-31 | PMCB Jul avg: -6.38% median: -6.42% win: 20% σ: 11.90% n: 5 2022-04-12 → 2026-07-31 | PMCB Aug avg: -6.93% median: -7.92% win: 25% σ: 13.11% n: 4 2022-04-12 → 2026-07-31 (current) | PMCB Sep avg: 1.27% median: -2.74% win: 50% σ: 17.34% n: 4 2022-04-12 → 2026-07-31 | PMCB Oct avg: 3.53% median: -1.57% win: 50% σ: 12.93% n: 4 2022-04-12 → 2026-07-31 | PMCB Nov avg: -3.25% median: -1.40% win: 50% σ: 10.36% n: 4 2022-04-12 → 2026-07-31 | PMCB Dec avg: -5.50% median: -5.42% win: 0% σ: 2.28% n: 4 2022-04-12 → 2026-07-31 |